4R3P
| Crystal structures of EGFR in complex with Mig6 | Descriptor: | Epidermal growth factor receptor, peptide from ERBB receptor feedback inhibitor 1 | Authors: | Park, E, Kim, N, Yi, Z, Cho, A, Kim, K, Ficarro, S.B, Park, A, Park, W.Y, Murray, B, Meyerson, M, Beroukim, R, Marto, J.A, Cho, J, Eck, M.J. | Deposit date: | 2014-08-17 | Release date: | 2015-08-12 | Last modified: | 2015-09-16 | Method: | X-RAY DIFFRACTION (2.905 Å) | Cite: | Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Nat.Struct.Mol.Biol., 22, 2015
|
|
8TJL
| EGFR kinase in complex with pyrazolopyrimidine covalent inhibitor | Descriptor: | 1-{3-[(4-amino-1-tert-butyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)oxy]azetidin-1-yl}propan-1-one, Epidermal growth factor receptor | Authors: | Beyett, T.S, Eck, M.J. | Deposit date: | 2023-07-22 | Release date: | 2024-02-14 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | ZNL0325, a Pyrazolopyrimidine-Based Covalent Probe, Demonstrates an Alternative Binding Mode for Kinases. J.Med.Chem., 67, 2024
|
|
1I3Z
| MURINE EAT2 SH2 DOMAIN IN COMPLEX WITH SLAM PHOSPHOPEPTIDE | Descriptor: | EWS/FLI1 ACTIVATED TRANSCRIPT 2, SIGNALING LYMPHOCYTIC ACTIVATION MOLECULE | Authors: | Lu, J, Poy, F, Morra, M, Terhorst, C, Eck, M.J. | Deposit date: | 2001-02-19 | Release date: | 2003-04-08 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (2.15 Å) | Cite: | Structural basis for the interaction of the free SH2 domain EAT-2 with
SLAM receptors in hematopoietic cells. Eur.J.Biochem., 20, 2001
|
|
7U99
| EGFR kinase in complex with a macrocyclic inhibitor | Descriptor: | 19-chloro-22-methoxy-8,9,11,12,14,15-hexahydro-21H-4,6-ethenopyrimido[5,4-m][1,4,7,10,15]benzotetraoxazacycloheptadecine, CITRATE ANION, Epidermal growth factor receptor | Authors: | Beyett, T.S, Eck, M.J. | Deposit date: | 2022-03-10 | Release date: | 2022-11-23 | Last modified: | 2023-10-25 | Method: | X-RAY DIFFRACTION (2.5 Å) | Cite: | Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19. J.Med.Chem., 65, 2022
|
|
7U98
| EGFR(T790M/V948R) in complex with a macrocyclic inhibitor | Descriptor: | 19-chloro-18-fluoro-22-methoxy-8,9,11,12,14,15-hexahydro-21H-4,6-ethenopyrimido[5,4-m][1,4,7,10,15]benzotetraoxazacycloheptadecine, Epidermal growth factor receptor | Authors: | Beyett, T.S, Eck, M.J. | Deposit date: | 2022-03-10 | Release date: | 2022-11-23 | Last modified: | 2023-10-25 | Method: | X-RAY DIFFRACTION (3.42 Å) | Cite: | Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19. J.Med.Chem., 65, 2022
|
|
7U9A
| EGFR in complex with a macrocyclic inhibitor | Descriptor: | 4-(5-chloro-4-fluoro-2-hydroxyanilino)-7-methoxyquinazolin-6-ol, CITRATE ANION, Epidermal growth factor receptor | Authors: | Beyett, T.S, Eck, M.J. | Deposit date: | 2022-03-10 | Release date: | 2022-11-23 | Last modified: | 2023-10-25 | Method: | X-RAY DIFFRACTION (2.6 Å) | Cite: | Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19. J.Med.Chem., 65, 2022
|
|
8DSW
| |
8EME
| EGFR(T790M/V948R) in complex with ZNL-0056 | Descriptor: | Epidermal growth factor receptor, N-{7-methyl-1-[(3S)-1-(prop-2-enoyl)azepan-3-yl]-1H-benzimidazol-2-yl}-5-(prop-2-enamido)thiophene-3-carboxamide | Authors: | Beyett, T.S, Eck, M.J. | Deposit date: | 2022-09-27 | Release date: | 2023-10-18 | Last modified: | 2024-07-10 | Method: | X-RAY DIFFRACTION (3.32 Å) | Cite: | Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality. Acs Cent.Sci., 10, 2024
|
|
8F1Z
| EGFR kinase in complex with Bayer #33 | Descriptor: | (2P)-3-(3-chloro-2-methoxyanilino)-2-[3-(2-methoxy-2-methylpropoxy)pyridin-4-yl]-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one, CITRIC ACID, Epidermal growth factor receptor | Authors: | Beyett, T.S, Eck, M.J. | Deposit date: | 2022-11-06 | Release date: | 2023-11-08 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity. Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
5D41
| EGFR kinase domain in complex with mutant selective allosteric inhibitor | Descriptor: | (2R)-2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2-phenyl-N-(1,3-thiazol-2-yl)acetamide, Epidermal growth factor receptor, MAGNESIUM ION, ... | Authors: | Yun, C.-H, Park, E, Eck, M.J. | Deposit date: | 2015-08-07 | Release date: | 2016-06-08 | Last modified: | 2023-09-27 | Method: | X-RAY DIFFRACTION (2.31 Å) | Cite: | Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature, 534, 2016
|
|
8F1Y
| EGFR kinase in complex with poziotinib | Descriptor: | 1-[4-[4-[[3,4-bis(chloranyl)-2-fluoranyl-phenyl]amino]-7-methoxy-quinazolin-6-yl]oxypiperidin-1-yl]propan-1-one, CITRIC ACID, Epidermal growth factor receptor | Authors: | Beyett, T.S, Eck, M.J. | Deposit date: | 2022-11-06 | Release date: | 2023-11-08 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (2.75 Å) | Cite: | Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity. Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
8F1H
| EGFR kinase in complex with TAS6417 (CLN-081) | Descriptor: | CITRIC ACID, Epidermal growth factor receptor, N-[(5P,8S,10R)-4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl]prop-2-enamide | Authors: | Beyett, T.S, Eck, M.J. | Deposit date: | 2022-11-05 | Release date: | 2023-11-08 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (2.8 Å) | Cite: | Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity. Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
8F1X
| EGFR kinase in complex with mobocertinib (TAK-788) | Descriptor: | Epidermal growth factor receptor, propan-2-yl 2-[[4-[2-(dimethylamino)ethyl-methyl-amino]-2-methoxy-5-(propanoylamino)phenyl]amino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate | Authors: | Beyett, T.S, Eck, M.J. | Deposit date: | 2022-11-06 | Release date: | 2023-11-08 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (2.3 Å) | Cite: | Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity. Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
8F1W
| EGFR(T790M/V948R) kinase in complex with poziotinib | Descriptor: | 1-[4-[4-[[3,4-bis(chloranyl)-2-fluoranyl-phenyl]amino]-7-methoxy-quinazolin-6-yl]oxypiperidin-1-yl]propan-1-one, Epidermal growth factor receptor | Authors: | Beyett, T.S, Eck, M.J. | Deposit date: | 2022-11-06 | Release date: | 2023-11-08 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (3.2 Å) | Cite: | Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity. Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
8F7P
| BRAF kinase in complex with LXH254 (naporafenib) | Descriptor: | N-{3-[2-(2-hydroxyethoxy)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl}-2-(trifluoromethyl)pyridine-4-carboxamide, Serine/threonine-protein kinase B-raf | Authors: | Tkacik, E, Li, K, Gonzalez Del-Pino, G, Eck, M.J. | Deposit date: | 2022-11-20 | Release date: | 2023-04-12 | Last modified: | 2024-05-22 | Method: | X-RAY DIFFRACTION (2.74 Å) | Cite: | Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. J.Biol.Chem., 299, 2023
|
|
8F7O
| BRAF kinase in complex with TAK580 (tovorafenib) | Descriptor: | 6-amino-5-chloro-N-[(1R)-1-(5-{[5-chloro-4-(trifluoromethyl)pyridin-2-yl]carbamoyl}-1,3-thiazol-2-yl)ethyl]pyrimidine-4-carboxamide, Serine/threonine-protein kinase B-raf | Authors: | Tkacik, E, Li, K, Gonzalez Del-Pino, G, Eck, M.J. | Deposit date: | 2022-11-20 | Release date: | 2023-04-12 | Last modified: | 2024-05-22 | Method: | X-RAY DIFFRACTION (3.54 Å) | Cite: | Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. J.Biol.Chem., 299, 2023
|
|
4Z32
| |
1EG3
| STRUCTURE OF A DYSTROPHIN WW DOMAIN FRAGMENT IN COMPLEX WITH A BETA-DYSTROGLYCAN PEPTIDE | Descriptor: | DYSTROPHIN | Authors: | Huang, X, Poy, F, Zhang, R, Joachimiak, A, Sudol, M, Eck, M.J. | Deposit date: | 2000-02-11 | Release date: | 2000-08-23 | Last modified: | 2024-02-07 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Structure of a WW domain containing fragment of dystrophin in complex with beta-dystroglycan. Nat.Struct.Biol., 7, 2000
|
|
1EG4
| STRUCTURE OF A DYSTROPHIN WW DOMAIN FRAGMENT IN COMPLEX WITH A BETA-DYSTROGLYCAN PEPTIDE | Descriptor: | BETA-DYSTROGLYCAN, DYSTROPHIN | Authors: | Huang, X, Poy, F, Zhang, R, Joachimiak, A, Sudol, M, Eck, M.J. | Deposit date: | 2000-02-11 | Release date: | 2000-08-23 | Last modified: | 2024-02-07 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Structure of a WW domain containing fragment of dystrophin in complex with beta-dystroglycan. Nat.Struct.Biol., 7, 2000
|
|
1F3M
| CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1 | Descriptor: | IODIDE ION, SERINE/THREONINE-PROTEIN KINASE PAK-ALPHA | Authors: | Lei, M, Lu, W, Meng, W, Parrini, M.-C, Eck, M.J, Mayer, B.J, Harrison, S.C. | Deposit date: | 2000-06-05 | Release date: | 2000-06-29 | Last modified: | 2024-02-07 | Method: | X-RAY DIFFRACTION (2.3 Å) | Cite: | Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell(Cambridge,Mass.), 102, 2000
|
|
1FMK
| |
6NYB
| Structure of a MAPK pathway complex | Descriptor: | 14-3-3 protein zeta, 5-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide, ADENOSINE-5'-DIPHOSPHATE, ... | Authors: | Park, E, Rawson, S, Li, K, Jeon, H, Eck, M.J. | Deposit date: | 2019-02-11 | Release date: | 2019-10-09 | Last modified: | 2024-10-23 | Method: | ELECTRON MICROSCOPY (4.1 Å) | Cite: | Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes. Nature, 575, 2019
|
|
1UX4
| Crystal structures of a Formin Homology-2 domain reveal a tethered-dimer architecture | Descriptor: | BNI1 PROTEIN | Authors: | Xu, Y, Moseley, J.B, Sagot, I, Poy, F, Pellman, D, Goode, B.L, Eck, M.J. | Deposit date: | 2004-02-19 | Release date: | 2004-03-11 | Last modified: | 2024-05-08 | Method: | X-RAY DIFFRACTION (3.3 Å) | Cite: | Crystal Structures of a Formin Homology-2 Domain Reveal a Tethered Dimer Architecture Cell(Cambridge,Mass.), 116, 2004
|
|
1UX5
| Crystal Structures of a Formin Homology-2 domain reveal a flexibly tethered dimer architecture | Descriptor: | BNI1 PROTEIN | Authors: | Xu, Y, Moseley, J.B, Sagot, I, Poy, F, Pellman, D, Goode, B.L, Eck, M.J. | Deposit date: | 2004-02-19 | Release date: | 2004-03-11 | Last modified: | 2024-10-23 | Method: | X-RAY DIFFRACTION (2.5 Å) | Cite: | Crystal Structures of a Formin Homology-2 Domain Reveal a Tethered Dimer Architecture Cell(Cambridge,Mass.), 116, 2004
|
|
2SHP
| TYROSINE PHOSPHATASE SHP-2 | Descriptor: | DODECANE-TRIMETHYLAMINE, SHP-2 | Authors: | Hof, P, Pluskey, S, Dhe-Paganon, S, Eck, M.J, Shoelson, S.E. | Deposit date: | 1997-12-01 | Release date: | 1999-02-16 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Crystal structure of the tyrosine phosphatase SHP-2. Cell(Cambridge,Mass.), 92, 1998
|
|